Table 1 Clinical phenotypes of 1215 1000IBD participants
From: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
| No. of participants | 1215 |
| Age (Median ± IQR) | 41 ± 25 |
| Sex | |
| Male (%) | 510 (41.97) |
| Female (%) | 705 (58.03) |
| Diagnosis | |
| Crohn’s Disease (%) | 615 (50.62) |
| Ulcerative Colitis (%) | 495 (40.74) |
| IBDU (%) | 61 (5.02) |
| Other (microscopic colitis, IBDI, reconsidering IBD diagnosis) (%) | 44 (3.62) |
| Montreal Classification | |
| A: Age of Onset | |
| A1 (%) | 159 (13.09) |
| A2 (%) | 710 (58.44) |
| A3 (%) | 253 (20.82) |
| L: Disease Location (CD only) | |
| L1 (%) | 224 (36.42) |
| L2 (%) | 120 (19.51) |
| L3 (%) | 255 (41.46) |
| L4 (%) | 65 (10.57) |
| B: Disease Behaviour (CD only) | |
| B1 (%) | 301 (48.94) |
| B2 (%) | 208 (33.82) |
| B3 (%) | 102 (16.58) |
| Perianal | 189 (30.73) |
| E: Disease Extent (UC only) | |
| E1 (%) | 57 (10.25) |
| E2 (%) | 162 (29.13) |
| E3 (%) | 299 (53.78) |
| S: Disease Severity (UC only) | |
| S1 (%) | 29 (5.22) |
| S2 (%) | 139 (25.00) |
| S3 (%) | 191 (34.35) |
| S4 (%) | 119 (21.40) |
| Age at Diagnosis in years (Median ± IQR) | 27 ± 19 |
| Disease Duration at Recruitment in years (Median ± IQR) | 8 ± 12 |
| Medication Exposure | |
| Steroids % | 90.07 |
| Steroids CD % | 91.99 |
| Steroids UC % | 88.28 |
| Steroids IBDU % | 88.33 |
| Immunosuppressors % | 68.32 |
| Immunosuppressors CD % | 79.08 |
| Immunosuppressors UC % | 56.97 |
| Immunosuppressors IBDU % | 56.67 |
| Biologicals % | 37.30 |
| Biologicals CD % | 55.07 |
| Biologicals UC % | 17.37 |
| Biologicals IBDU % | 25.00 |
| Mesalazines % | 44.34 |
| Mesalazines CD % | 18.06 |
| Mesalazines UC % | 70.99 |
| Mesalazines IBDU % | 83.33 |
| Average Disease Activitya | |
| HBI (Average ± Standard Deviation) | 2.99 ± 3.18 |
| SSCAI (Average ± Standard Deviation) | 1.61 ± 1.97 |